Histological classification and cytology reporting format described in General Rules for the Description of Thyroid Cancer, the 8^th edition (2019) (the Japanese General Rules) were briefly introduced. Moreover, the differences between “the Japanese General Rules”, and WHO Histological Classification, the 4^th edition (2017) and The Bethesda System for Reporting Thyroid Cytopathology, the 2^nd edition (2018) were also explained. The Japanese General Rules did not accept the borderline lesions of thyroid tumor which were newly shown in WHO Histological Classification. We believe it is not necessary to introduce these borderline lesions in daily practice in Japan. Borderline lesions were proposed for avoiding over-surgery for thyroid cancer patients. In the United States, when the patient is diagnosed as malignant on cytology, total thyroidectomy is generally recommended. However, there is no over-surgery in Japan, because surgeons have several choices of treatment for thyroid cancer patients. This article is the first that the Japanese General Rules was shown by foreign language. Therefore, this will be advantageous to us when we present our opinion concerning histology and cytology of thyroid tumor to the world.

组织学分类和细胞学报告格式一般规则甲状腺癌的说明所述，8^个版（2019）（日本总则）简要介绍了。另外，“日本通则”，和WHO组织学分类之间的差别，这4^个版（2017）和Bethesda系统用于报告甲状腺细胞病理学，2^次版（2018 年）也进行了解释。日本通则不接受WHO组织学分类中新显示的甲状腺肿瘤临界病变。我们认为没有必要在日本的日常实践中引入这些临界病变。提出边界病变是为了避免甲状腺癌患者过度手术。在美国，当细胞学诊断为恶性时，一般推荐甲状腺全切除术。然而，日本并没有过度手术，因为外科医生对甲状腺癌患者有多种治疗选择。这篇文章是第一次用外文显示日本通则。因此，这将有利于我们向世界展示我们对甲状腺肿瘤组织学和细胞学的看法。